Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Mantle Cell Lymphoma News

News
Real-World Outcomes of Brexucabtagene Autoleucel Treatment in Patients With Relapsed or Refractory Mantle Cell Lymphoma With High-Risk Features
02/14/2024

Grace Taylor

Grace Taylor
A recent study investigated real-world outcomes of brexu-cel treatment in patients with relapsed or refractory mantle cell lymphoma with high-risk features, including deletion of TP53 or 17p, Ki-67 proliferation index, and whether the...
A recent study investigated real-world outcomes of brexu-cel treatment in patients with relapsed or refractory mantle cell lymphoma with high-risk features, including deletion of TP53 or 17p, Ki-67 proliferation index, and whether the...
A recent study investigated...
02/14/2024
Journal of Clinical Pathways
Conference Coverage
Bendamustine-Rituximab Followed by Rituximab ± Lenalidomide for Mantle Cell Lymphoma
12/10/2022

Katie Herman 

Katie Herman 
Mitchell R Smith, MD, and colleagues presented data at the 64th ASH Annual Meeting and Exposition on whether progression-free survival is prolonged by the addition of bortezomib to bendamustine-rituximab induction and/or by the addition of...
Mitchell R Smith, MD, and colleagues presented data at the 64th ASH Annual Meeting and Exposition on whether progression-free survival is prolonged by the addition of bortezomib to bendamustine-rituximab induction and/or by the addition of...
Mitchell R Smith, MD, and...
12/10/2022
Journal of Clinical Pathways
News
Study Indicates Late Effects in Mantle Cell Lymphoma Treatment With or Without Transplantation Have Minimal Impact
09/12/2022

Yvette C Terrie

Yvette C Terrie
Results from a recent study indicated that mantle cell lymphoma patients have higher relative risks of respiratory, blood, and infectious disease compared to healthy comparators and that late effects varied very little by treatment with or...
Results from a recent study indicated that mantle cell lymphoma patients have higher relative risks of respiratory, blood, and infectious disease compared to healthy comparators and that late effects varied very little by treatment with or...
Results from a recent study...
09/12/2022
Journal of Clinical Pathways

Advertisement

News
Exploring Radiation Therapy for Orbital Involvement in Patients with Mantle Cell Lymphoma
09/12/2022

Yvette C Terrie

Yvette C Terrie
Mantle cell lymphoma with optic nerve involvement is a rare oncologic process, with whole-brain radiation therapy conventionally utilized as a palliative treatment.
Mantle cell lymphoma with optic nerve involvement is a rare oncologic process, with whole-brain radiation therapy conventionally utilized as a palliative treatment.
Mantle cell lymphoma with optic...
09/12/2022
Journal of Clinical Pathways
News
Exploring PD-1/PD-L1 Expression in Mantle Cell Lymphoma and its Significance as an Immune Check Point Inhibitor
08/26/2022

Yvette C Terrie

Yvette C Terrie
Findings from a recent study suggest that neither PD-1 nor its ligands represent relevant targets for mantle cell lymphoma treatment, however, age may impact the efficiency of immune checkpoint inhibitors.
Findings from a recent study suggest that neither PD-1 nor its ligands represent relevant targets for mantle cell lymphoma treatment, however, age may impact the efficiency of immune checkpoint inhibitors.
Findings from a recent study...
08/26/2022
Journal of Clinical Pathways
News
Autologous Stem-Cell Transplant Underutilized Among Patients With Mantle Cell Lymphoma in US Community Settings
08/16/2022

Yvette C Terrie

Yvette C Terrie
Study findings reveal that among a large cohort of patients treated primarily in the US community setting, one in four patients received cytarabine or autologous stem-cell transplant consolidation, indicating the need to develop treatments...
Study findings reveal that among a large cohort of patients treated primarily in the US community setting, one in four patients received cytarabine or autologous stem-cell transplant consolidation, indicating the need to develop treatments...
Study findings reveal that among...
08/16/2022
Journal of Clinical Pathways

Advertisement

News
Survey Explores Prescriber Perceptions and Preferences Regarding First Line Therapy for MCL
07/27/2022

Ellen Kurek

Ellen Kurek
A survey evaluated first-line therapy preferences for treatment-naïve patients with MCL in routine practice and perceptions surrounding benefits and risks of the lenalidomide plus rituximab plus venetoclax triplet regimen.
A survey evaluated first-line therapy preferences for treatment-naïve patients with MCL in routine practice and perceptions surrounding benefits and risks of the lenalidomide plus rituximab plus venetoclax triplet regimen.
A survey evaluated first-line...
07/27/2022
Journal of Clinical Pathways
News
Evaluating Attrition Rates and Treatment Outcomes Among Patients With MCL
07/14/2022

Ellen Kurek

Ellen Kurek
Findings from a recent real-world analysis on patients with mantle cell lymphoma revealed high attrition rates, as well as a need for more effective treatment options for those in earlier lines of therapy.
Findings from a recent real-world analysis on patients with mantle cell lymphoma revealed high attrition rates, as well as a need for more effective treatment options for those in earlier lines of therapy.
Findings from a recent...
07/14/2022
Journal of Clinical Pathways
News
Real-World Treatment Patterns Among Patients With Mantle Cell Lymphoma
05/27/2022

Marta Rybczynski

Marta Rybczynski
For the treatment of MCL, a recent study found that bendamustine and rituximab was the most used frontline regimen, while BTK inhibitors were the most used agents in later lines of therapy.
For the treatment of MCL, a recent study found that bendamustine and rituximab was the most used frontline regimen, while BTK inhibitors were the most used agents in later lines of therapy.
For the treatment of MCL, a...
05/27/2022
Journal of Clinical Pathways

Advertisement

News
Cost-Effectiveness of Bruton Tyrosine Kinase Inhibitors for the Treatment of Relapsed or Refractory MCL
04/27/2022

Ellen Kurek

Ellen Kurek
Second-generation BTKis acalabrutinib and zanubrutinib may provide additional progression-free survival among patients with relapsed or refractory mantle cell lymphoma, compared with first-generation BTKi ibrutinib, according to an early...
Second-generation BTKis acalabrutinib and zanubrutinib may provide additional progression-free survival among patients with relapsed or refractory mantle cell lymphoma, compared with first-generation BTKi ibrutinib, according to an early...
Second-generation BTKis...
04/27/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use